[[{“value”:”
Bayer reported a Phase 3 test of Kerendia in heart failure led to statistically significant reductions in cardiovascular death and hospitalizations. Detailed results will be presented during the European Society of Cardiology annual meeting in September.
The post Bayer Looks to Expand Kerendia’s Label to Heart Failure After Phase 3 Win appeared first on MedCity News.
“}]]
